-+ 0.00%
-+ 0.00%
-+ 0.00%

Does Stronger 2025 Results And Narrowing Losses Reshape The Bull Case For Ascendis Pharma (ASND)?

Simply Wall St·02/18/2026 08:27:32
Listen to the news
  • In February 2026, Ascendis Pharma A/S reported its fourth-quarter 2025 results, with sales of €247.5 million and a net loss of €33.56 million, and full-year 2025 sales of €720.13 million alongside a net loss of €228.03 million, all showing year-on-year improvement in both revenue and losses per share.
  • These earnings, which combined much higher sales with smaller losses, prompted several major Wall Street firms to reiterate positive views on Ascendis Pharma’s prospects, highlighting how operational progress is reshaping perceptions of the company’s risk-reward profile.
  • We’ll now examine how this combination of sharply higher revenue and narrowing losses could influence Ascendis Pharma’s existing investment narrative.

Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

Ascendis Pharma Investment Narrative Recap

To own Ascendis Pharma, you essentially need to believe its TransCon platform can turn rising sales from YORVIPATH, SKYTROFA and future approvals like TransCon CNP into a sustainable, profitable rare disease franchise. The latest results, with full year 2025 revenue of €720.13 million and smaller net losses, support that direction but do not remove the near term risk that high R&D and SG&A spending keep cash burn elevated if growth slows or key approvals slip.

Among recent announcements, the Week 52 COACH trial data for TransCon CNP plus TransCon hGH in achondroplasia stands out, especially with FDA Priority Review and a PDUFA date of 28 February 2026. Positive regulatory outcomes here could meaningfully expand Ascendis Pharma’s addressable market and ease concerns about reliance on a few core products, while any setback would sharpen focus on the company’s ongoing losses and funding needs.

Yet against this improving revenue story, investors should also be aware that Ascendis still faces concentrated product risk and sustained cash burn if...

Read the full narrative on Ascendis Pharma (it's free!)

Ascendis Pharma's narrative projects €2.2 billion revenue and €826.6 million earnings by 2028.

Uncover how Ascendis Pharma's forecasts yield a $277.16 fair value, a 24% upside to its current price.

Exploring Other Perspectives

ASND 1-Year Stock Price Chart
ASND 1-Year Stock Price Chart

Some of the most optimistic analysts were already assuming roughly €2.9 billion in revenue and €1.9 billion in earnings by 2028, which is a far more aggressive path than the baseline view. When you set those assumptions against the new 2025 numbers and the very real risk that a setback for TransCon CNP or pricing pressure could bite, it highlights how widely opinions can differ and why it is worth weighing several possible futures for Ascendis before deciding where you stand.

Explore 4 other fair value estimates on Ascendis Pharma - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.